- Kits
- Assays and Reagents
- Instruments
- Software
Pharmacogenomics Market size was valued at USD 7,398.9 million in 2023 and is poised to grow at a CAGR of 11.2% from 2024-2030. Pharmacogenomics is the study of how a person's genetic composition affects their reaction to medications. It combines the principles of pharmacology and genomics. Pharmacogenomics analyses genetic variations to adapt pharmacological therapy to maximize efficacy, reduce side effects, and improve patient outcomes. The pharmacogenomics market encompasses the products, services, and technologies used in genetic testing for personalized medicine applications. It is driven by advancements in genomic technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and microarray analysis. These technologies enable healthcare providers to identify genetic biomarkers that influence drug metabolism, efficacy, and safety, thereby facilitating personalized treatment decisions.
The growing prevalence of chronic diseases, increasing adoption of personalized medicine approaches, advancements in genomic research and technology, government initiatives promoting precision medicine and increase in funding to the research are the key drivers of the pharmacogenomics market. Over the next five years, genomic data from over 60 million patients are expected to be generated within the healthcare system. Global investment is totalling over US$ 4 billion in at least 14 countries. These factors contribute to the market's expansion as healthcare systems worldwide recognize the potential of pharmacogenomics to improve patient care and reduce healthcare costs by avoiding ineffective treatments and increasing patient compliance by reducing adverse drug reactions. However, the market encounters numerous obstacles, including the high cost of genetic testing, ethical and regulatory concerns about genetic data privacy, and the need for standardized protocols, and lack of proper education and awareness among healthcare practitioners is one of the main restraints. Also, as the implementation of these complex procedures in routine clinical practice is still a milestone to achieve. Complexity in interpreting the genetic variation, lack of proper tools and infrastructure and slower adaptation rate are the main challenges faced in in growing countries. Despite these challenges, the pharmacogenomics market is expected to expand significantly, driven by ongoing research, technology developments, and rising patient desire for personalized treatment solutions. As the field continues to evolve, it promises to revolutionize the way medications are prescribed and administered based on individual genetic profiles.
Recent Development In The Pharmacogenomics Market:
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the research in oncology is the first and dominant application of this market. The new trend in Pharmacogenomics market is continuous technological advancements in sequencing and PCR technologies, rise in personalised medicine has drastically increased the market share as people find it convenient. The introduction of AI in pharmacogenomic diagnostics is also an emerging trend for the Global Pharmacogenomics market. According to the World Health Organization (WHO), cancer was projected to kill approximately 10 million people in 2020. According to the American Cancer Society, the global burden of carcinoma is expected to reach 27.5 million new cases and 16.3 million deaths by 2040. Such high numbers indicate that the increased incidence of cancer is generating a need for new treatment methods that's where cancer pharmacogenomics comes in. Integration into regular clinical practice, genomic data integration into personalised electronic health records (EHRs) are the main opportunities of this market. The next steps for companies are to establish in developed countries and expand into emerging markets. New products such as DTC-IVGD Direct To Consumer – In Vitro Genetic Diagnostics is the new focus of the companies.
Pharmacogenomics Market size was valued at USD 7,398.9 million in 2023 and is poised to grow at a CAGR of 11.2% from 2024-2030.
The Pharmacogenomics market key players are: Abbott; bioMérieux; Thermo Fisher Scientific Inc., F. Hoffmann-La Roche, Bio-Rad Laboratories, and Biomerieux.
The growing burden of chronic diseases, technological advancements in genomics , patient demand for personalized healthcare, adaptation of personalised healthcare and pharmaceutical R&D investments are the major factors that are driving the growth of the global market by incidence
North America is projected to lead the global Pharmacogenomics market as the presence of robust research and healthcare infrastructure and substantial funding compared the rest of the world.
PCRs have the largest share in Pharmacogenomics Market by technique.
1. Executive Summary |
2. Global Pharmacogenomics Market Introduction |
2.1.Global Pharmacogenomics Market - Taxonomy |
2.2.Global Pharmacogenomics Market - Definitions |
2.2.1.Product |
2.2.2.Services |
2.2.3.Application |
2.2.4. Technique |
2.2.5.Region |
3. Global Pharmacogenomics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Pharmacogenomics Market Analysis, 2019 - 2023 and Forecast 2024 -2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Pharmacogenomics Market By Product, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
5.1. Kits |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Assays and Reagents |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Instruments |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Software |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Pharmacogenomics Market By Services, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
6.1. Genotyping |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. SNP Identification |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Pharmacogenetic Testing |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Other Services |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Pharmacogenomics Market By Application, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
7.1. Oncology |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Infectious Diseases |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Neurology/Psychiatry |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Cardiovascular |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Others |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. Global Pharmacogenomics Market By Technique, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
8.1. DNA Sequencing/Next Generation Sequencing (NGS) |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Nucleic Acid Amplification Tests (NAATs) |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Polymerase Chain Reaction |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Mass Spectrophotometry |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Gel Electrophoresis |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Fluorescent In-situ Hybridization |
8.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
8.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.6.3. Market Opportunity Analysis |
8.7. Microarray |
8.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
8.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.7.3. Market Opportunity Analysis |
8.8. Others |
8.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
8.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.8.3. Market Opportunity Analysis |
9. Global Pharmacogenomics Market By Region, 2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 -2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10. North America Pharmacogenomics Market ,2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
10.1. Product Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Kits |
10.1.2.Assays and Reagents |
10.1.3.Instruments |
10.1.4.Software |
10.2. Services Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Genotyping |
10.2.2.SNP Identification |
10.2.3.Pharmacogenetic Testing |
10.2.4.Other Services |
10.3. Application Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oncology |
10.3.2.Infectious Diseases |
10.3.3.Neurology/Psychiatry |
10.3.4.Cardiovascular |
10.3.5.Others |
10.4. Technique Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.DNA Sequencing/Next Generation Sequencing (NGS) |
10.4.2.Nucleic Acid Amplification Tests (NAATs) |
10.4.3.Polymerase Chain Reaction |
10.4.4.Mass Spectrophotometry |
10.4.5.Gel Electrophoresis |
10.4.6.Fluorescent In-situ Hybridization |
10.4.7.Microarray |
10.4.8.Others |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11. Europe Pharmacogenomics Market ,2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
11.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Kits |
11.1.2.Assays and Reagents |
11.1.3.Instruments |
11.1.4.Software |
11.2. Services Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Genotyping |
11.2.2.SNP Identification |
11.2.3.Pharmacogenetic Testing |
11.2.4.Other Services |
11.3. Application Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oncology |
11.3.2.Infectious Diseases |
11.3.3.Neurology/Psychiatry |
11.3.4.Cardiovascular |
11.3.5.Others |
11.4. Technique Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.DNA Sequencing/Next Generation Sequencing (NGS) |
11.4.2.Nucleic Acid Amplification Tests (NAATs) |
11.4.3.Polymerase Chain Reaction |
11.4.4.Mass Spectrophotometry |
11.4.5.Gel Electrophoresis |
11.4.6.Fluorescent In-situ Hybridization |
11.4.7.Microarray |
11.4.8.Others |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
11.5.6.Rest of EU |
12. Asia Pacific (APAC) Pharmacogenomics Market ,2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
12.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Kits |
12.1.2.Assays and Reagents |
12.1.3.Instruments |
12.1.4.Software |
12.2. Services Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Genotyping |
12.2.2.SNP Identification |
12.2.3.Pharmacogenetic Testing |
12.2.4.Other Services |
12.3. Application Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oncology |
12.3.2.Infectious Diseases |
12.3.3.Neurology/Psychiatry |
12.3.4.Cardiovascular |
12.3.5.Others |
12.4. Technique Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.DNA Sequencing/Next Generation Sequencing (NGS) |
12.4.2.Nucleic Acid Amplification Tests (NAATs) |
12.4.3.Polymerase Chain Reaction |
12.4.4.Mass Spectrophotometry |
12.4.5.Gel Electrophoresis |
12.4.6.Fluorescent In-situ Hybridization |
12.4.7.Microarray |
12.4.8.Others |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13. Middle East and Africa (MEA) Pharmacogenomics Market ,2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
13.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Kits |
13.1.2.Assays and Reagents |
13.1.3.Instruments |
13.1.4.Software |
13.2. Services Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Genotyping |
13.2.2.SNP Identification |
13.2.3.Pharmacogenetic Testing |
13.2.4.Other Services |
13.3. Application Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oncology |
13.3.2.Infectious Diseases |
13.3.3.Neurology/Psychiatry |
13.3.4.Cardiovascular |
13.3.5.Others |
13.4. Technique Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.DNA Sequencing/Next Generation Sequencing (NGS) |
13.4.2.Nucleic Acid Amplification Tests (NAATs) |
13.4.3.Polymerase Chain Reaction |
13.4.4.Mass Spectrophotometry |
13.4.5.Gel Electrophoresis |
13.4.6.Fluorescent In-situ Hybridization |
13.4.7.Microarray |
13.4.8.Others |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Pharmacogenomics Market ,2019 - 2023 and Forecast 2024 -2030 (Sales Value USD Million) |
14.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Kits |
14.1.2.Assays and Reagents |
14.1.3.Instruments |
14.1.4.Software |
14.2. Services Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Genotyping |
14.2.2.SNP Identification |
14.2.3.Pharmacogenetic Testing |
14.2.4.Other Services |
14.3. Application Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oncology |
14.3.2.Infectious Diseases |
14.3.3.Neurology/Psychiatry |
14.3.4.Cardiovascular |
14.3.5.Others |
14.4. Technique Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.DNA Sequencing/Next Generation Sequencing (NGS) |
14.4.2.Nucleic Acid Amplification Tests (NAATs) |
14.4.3.Polymerase Chain Reaction |
14.4.4.Mass Spectrophotometry |
14.4.5.Gel Electrophoresis |
14.4.6.Fluorescent In-situ Hybridization |
14.4.7.Microarray |
14.4.8.Others |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 -2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Abbott Laboratories, Inc. |
15.2.2.Agilent Technologies |
15.2.3.Assurex Health, Inc. |
15.2.4.AstraZeneca |
15.2.5.Becton, Dickinson and Company (BD) |
15.2.6.Bio-Rad Laboratories, Inc. |
15.2.7.Bristol-Myers Squibb Company |
15.2.8.Future Science Group |
15.2.9.GE Healthcare |
15.2.10.Genentech, Inc. |
15.2.11.GeneTech |
15.2.12.Hoffmann-La Roche Ltd. |
15.2.13.Illumina, Inc. |
15.2.14.Johnson & Johnson |
15.2.15.Merck & Co., Inc. |
15.2.16.Myriad Genetics, Inc. |
15.2.17.Novartis AG |
15.2.18.Pathway Genomics |
15.2.19.PerkinElmer, Inc. |
15.2.20.Qiagen N.V. |
15.2.21.Roche Diagnostics |
15.2.22.Siemens Healthineers |
15.2.23.Teva Pharmaceutical Industries Ltd. |
15.2.24.Thermo Fisher Scientific Inc. |
16. Research Methodology |
17. Appendix and Abbreviations |